In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Diabetic kidney disease (DKD) and cardiovascular disease (CVD) are major complications of type 2 diabetes (T2D).
• Current treatments for T2D-associated DKD and CVD have limitations in preventing disease progression.
• Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has shown potential in improving cardiorenal outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of finerenone in a large, pooled population of patients with T2D and chronic kidney disease (CKD).
• To assess the impact of finerenone on cardiovascular and kidney composite endpoints.
• To analyze finerenone's effects across different subgroups of patients with T2D and CKD.

Main Methods:

• Pooled analysis of two large, randomized, double-blind, placebo-controlled trials (FIDELIO-DKD and FIGARO-DKD).
• Inclusion of patients with T2D and CKD, stratified by baseline risk factors.
• Primary composite endpoint included kidney disease progression and cardiovascular death.

Main Results:

• Finerenone significantly reduced the risk of kidney disease progression (e.g., end-stage kidney disease or doubling of serum creatinine) by X% compared to placebo.
• Finerenone significantly decreased the risk of major adverse cardiovascular events (MACE) by Y% compared to placebo.
• Consistent benefits were observed across various subgroups, including patients with different stages of CKD and CVD risk.

Conclusions:

• Finerenone demonstrated significant cardiorenal protective effects in patients with T2D and CKD.
• The findings support finerenone as a valuable therapeutic option for reducing the burden of cardiorenal complications in this high-risk population.
• The FIDELITY analysis provides robust evidence for finerenone's efficacy and safety profile.